Brief: Arrowhead Pharmaceuticals Presents Phase 3 Shasta-3 And Shasta-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events In Patients With Severe Hypertriglyceridemia
30/08/2026 16:33
BRIEF-Arrowhead Pharmaceuticals Presents Phase 3 Shasta-3 And Shasta-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events In Patients With Severe Hypertriglyceridemia Aug 30 (Reuters) - Arrowhead Pharmaceuticals, Inc. ARWR.O:
ARROWHEAD PHARMACEUTICALS PRESENTS PHASE 3 SHASTA-3 AND SHASTA-4 DATA DEMONSTRATING PLOZASIRAN REDUCED ACUTE PANCREATITIS EVENTS IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA
ARROWHEAD PHARMACEUTICALS - TO FILE SUPPLEMENTAL NDA WITH U.S. FDA BY YEAR-END 2026 USING PRIORITY REVIEW VOUCHER
ARROWHEAD PHARMACEUTICALS - PLOZASIRAN DEMONSTRATED FAVORABLE SAFETY AND TOLERABILITY PROFILE IN PHASE 3 STUDIES
Source text: ID:nBw8Xh7XGa
Further company coverage: ARWR.O
(Reporting by Gargi Gupta)
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers